CD20+T:

Anna Chiara Mazzeo1, Laura Calabresi1, Valentina Damato1,2

  • 1Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.

概括

新的研究强调了CD20+ T细胞,一种促炎子集,作为多发性硬化症 (MS) 病理学的潜在驱动因素. 它们因抗CD20疗法而耗尽可能解释MS患者的治疗疗效.